During the last three months, 8 analysts shared their evaluations of Arcus Biosciences (NYSE:RCUS), revealing diverse outlooks from bullish to bearish. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Analysts’ evaluations of 12-month price targets offer additional insights, showcasing an average target of $25.12, with a high estimate of $30.00 and a low estimate of $20.00. Marking an increase of 1.17%, the current average surpasses the previous average price target of $…